A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd
STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is published in the June edition of MedNous, through a written commentary by CEO Anders Månsson.
In order to further attract the attention of potential partners and increase their interest in RhoVac's achievements as well as plans for the future, RhoVac's CEO Anders Månsson has written a commentary on the company in the latest edition of MedNous that was published last week.
CEO Anders Månsson comments: "It is important that we communicate on RhoVac more broadly than what can be accomplished in direct bi-lateral meetings, whether physical or digital. By reaching out also via the international press, informing on our achievements and our plans, we can also reach a broader audience and that is important from a business perspective."
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at...
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...